Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Rifabutin | 1 | 2019 | 20 | 0.79 | Why? |
| Serum Amyloid P-Component | 1 | 2021 | 193 | 0.78 | Why? |
| Antibiotics, Antitubercular | 1 | 2019 | 65 | 0.76 | Why? |
| Leukocyte L1 Antigen Complex | 1 | 2021 | 238 | 0.75 | Why? |
| Brucellosis | 1 | 2019 | 49 | 0.74 | Why? |
| Diphtheria-Tetanus Vaccine | 1 | 2018 | 16 | 0.72 | Why? |
| Cholinergic Antagonists | 1 | 2018 | 56 | 0.72 | Why? |
| Otitis Media with Effusion | 1 | 2017 | 39 | 0.68 | Why? |
| Rabies Vaccines | 1 | 2018 | 106 | 0.67 | Why? |
| Nutrition Assessment | 1 | 2021 | 527 | 0.66 | Why? |
| Otitis Media | 1 | 2017 | 106 | 0.63 | Why? |
| Thorax | 1 | 2020 | 1873 | 0.42 | Why? |
| BCG Vaccine | 1 | 2020 | 1137 | 0.40 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.34 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.29 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.29 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.27 | Why? |
| Ultrasonography | 1 | 2020 | 4409 | 0.27 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.27 | Why? |
| Ofloxacin | 1 | 2019 | 23 | 0.20 | Why? |
| Sacroiliitis | 1 | 2019 | 24 | 0.20 | Why? |
| Carbonic Anhydrase I | 1 | 2018 | 4 | 0.19 | Why? |
| Carbonic Anhydrase II | 1 | 2018 | 8 | 0.19 | Why? |
| Anti-Bacterial Agents | 2 | 2018 | 10083 | 0.19 | Why? |
| alpha-Glucosidases | 1 | 2018 | 39 | 0.19 | Why? |
| Acetylcholinesterase | 1 | 2018 | 62 | 0.19 | Why? |
| Mean Platelet Volume | 1 | 2020 | 203 | 0.19 | Why? |
| Acetylcholine | 1 | 2018 | 53 | 0.18 | Why? |
| Blood Group Antigens | 1 | 2020 | 202 | 0.18 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.16 | Why? |
| Ceftriaxone | 1 | 2019 | 365 | 0.16 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.16 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.16 | Why? |
| Diabetes Mellitus | 1 | 2018 | 8207 | 0.15 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.15 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.15 | Why? |
| Acinetobacter baumannii | 1 | 2018 | 378 | 0.14 | Why? |
| Troponin | 1 | 2021 | 1058 | 0.14 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.13 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.13 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.13 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.13 | Why? |
| Pseudomonas aeruginosa | 1 | 2018 | 652 | 0.13 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.13 | Why? |
| Radiography | 1 | 2021 | 1576 | 0.13 | Why? |
| Molecular Structure | 1 | 2018 | 1539 | 0.12 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.12 | Why? |
| Aged | 8 | 2021 | 215776 | 0.12 | Why? |
| Dengue Virus | 1 | 2019 | 910 | 0.11 | Why? |
| Structure-Activity Relationship | 1 | 2018 | 2219 | 0.11 | Why? |
| Staphylococcus aureus | 1 | 2018 | 844 | 0.11 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.11 | Why? |
| Travel-Related Illness | 1 | 2019 | 1357 | 0.11 | Why? |
| Lung | 1 | 2020 | 31049 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.11 | Why? |
| Escherichia coli | 1 | 2018 | 1547 | 0.11 | Why? |
| Hepatitis B virus | 1 | 2018 | 882 | 0.10 | Why? |
| Humans | 21 | 2021 | 930598 | 0.10 | Why? |
| Hepatitis B | 1 | 2018 | 888 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Microbial Sensitivity Tests | 1 | 2018 | 2886 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.10 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.09 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
| Adult | 9 | 2021 | 244371 | 0.09 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.09 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.08 | Why? |
| Male | 12 | 2021 | 367725 | 0.08 | Why? |
| Mortality | 2 | 2021 | 7132 | 0.08 | Why? |
| Dengue | 1 | 2019 | 1565 | 0.08 | Why? |
| Fever | 2 | 2020 | 7795 | 0.08 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.08 | Why? |
| Turkey | 3 | 2021 | 3937 | 0.08 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2019 | 7268 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.07 | Why? |
| Emergency Medical Services | 1 | 2020 | 3557 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.07 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.07 | Why? |
| Female | 10 | 2021 | 380317 | 0.06 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Specimen Handling | 1 | 2017 | 6190 | 0.05 | Why? |
| Sri Lanka | 1 | 2019 | 241 | 0.05 | Why? |
| Muscle Weakness | 1 | 2020 | 406 | 0.04 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.04 | Why? |
| Nails | 1 | 2018 | 143 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Malaysia | 1 | 2019 | 1116 | 0.03 | Why? |
| Myalgia | 1 | 2020 | 1015 | 0.03 | Why? |
| Creatinine | 1 | 2020 | 1443 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Vaccination | 1 | 2018 | 19050 | 0.03 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Exanthema | 1 | 2019 | 1097 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Hospitals, University | 1 | 2021 | 4173 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.02 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.02 | Why? |
| Family Characteristics | 1 | 2018 | 2551 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Cough | 1 | 2020 | 4891 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Treatment Outcome | 2 | 2020 | 51732 | 0.02 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2021 | 17020 | 0.01 | Why? |
| Olfaction Disorders | 1 | 2020 | 3704 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 8811 | 0.01 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
Güçlü's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(119)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(51)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_